Latest Administration News

CVC Limited announces the planned resignation of CEO Mark Avery by July 2026, triggering a leadership reshuffle with Executive Chair Craig Treasure set to become Managing Director and Andrew Ashwood stepping in as CEO.

US Masters Residential Property Group (URF) sold 40 properties for US$48.59 million in Q1 2026, cutting its portfolio to 121 assets valued at US$123.21 million. The Group targets a full exit by year-end amid stable market conditions despite geopolitical and local political challenges.

Micro-X's U.S. subsidiary has won a $1.3 million contract extension from the U.S. Department of Homeland Security to push forward its Passenger Self-Screening Checkpoint program, moving closer to real-world airport trials.

SDI Limited's acquisition by Beijing Guoci's subsidiary advances with ASIC registration of the scheme booklet and court approval to convene a shareholder meeting. The all-cash offer at a 53–58% premium awaits shareholder and final court approval.

Challenger Gold's Pre-Feasibility Study for the Hualilan Project delivers a robust US$1.45 billion pre-tax NPV, 1.84 million ounces gold equivalent production, and a low upfront capital strategy.

Alcidion Group has acquired Telstra Health's Kyra flow products for $3 million upfront, adding 33 long-term customers and boosting recurring revenue in key Australian states.

Saluda Medical’s Australian arm has secured ASIC approval to bypass standalone audited financial reports, cutting costs and streamlining compliance.

Chariot Resources has broadened its Nigerian lithium acquisition by adding a key small-scale mining licence and converting three leases to mining leases, extending the acquisition timeline and increasing regulatory costs.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Pacific Edge launches a NZ$6 million retail share offer at NZ$0.17 per share following a NZ$25.4 million institutional placement, aiming to strengthen its balance sheet and support Medicare reimbursement efforts for its bladder cancer diagnostics.

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.